P
Philippe Moreau
Researcher at University of Nantes
Publications - 693
Citations - 52995
Philippe Moreau is an academic researcher from University of Nantes. The author has contributed to research in topics: Multiple myeloma & Medicine. The author has an hindex of 104, co-authored 517 publications receiving 42530 citations. Previous affiliations of Philippe Moreau include University of Grenoble & National and Kapodistrian University of Athens.
Papers
More filters
Journal ArticleDOI
All transplantation-eligible patients with myeloma should receive ASCT in first response
Philippe Moreau,Michel Attal +1 more
TL;DR: The optimal approach to the treatment of multiple myeloma is to propose the most effective treatment that should involve the use of frontline ASCT in young patients eligible for high-dose therapy (HDT) and autologous stem cell transplantation (ASCT).
Journal ArticleDOI
A novel complete blood count-based score to screen for myelodysplastic syndrome in cytopenic patients.
Robin Boutault,Pierre Peterlin,Marouane Boubaya,Katja Sockel,Patrice Chevallier,Alice Garnier,Thierry Guillaume,Amandine Le Bourgeois,Camille Debord,Catherine Godon,Yannick Le Bris,Olivier Theisen,Frank Kroschinsky,Philippe Moreau,Marie C. Béné,Uwe Platzbecker,Marion Eveillard +16 more
TL;DR: The MDS‐CBC score is an easy and fast tool to exclude or suspect MDS in unselected patients with cytopenia of unknown reasons at the time of analysis, by prompting blood smear examination.
Journal ArticleDOI
T-cell redirecting bispecific antibodies in multiple myeloma: a revolution?
Philippe Moreau,Cyrille Touzeau +1 more
TL;DR: Early-phase clinical trials targeting B-cell maturation antigen, GPRC5D or FcRH5, have demonstrated a favorable safety profile and promising efficacy data in triple-class refractory multiple myeloma.
Journal ArticleDOI
Comparison of Sebia Free Light Chain Assay With Freelite Assay for the Clinical Management of Diagnosis, Response, and Relapse Assessment in Multiple Myeloma
TL;DR: The Sebia FLC assay provides inequivalent absolute results from the Freelite assay, despite lower absolute FLC values, the kinetics of response and relapse is exactly the same.
Journal ArticleDOI
Pomalidomide, cyclophosphamide, and dexamethasone for relapsed/refractory multiple myeloma patients in a real-life setting: a single-center retrospective study
Sabrina Trudel,Benoit Tessoulin,Maxime Jullien,Nicolas Blin,Thomas Gastinne,Beatrice Mahe,Viviane Dubruille,Antoine Bonnet,Anne Lok,Patrice Chevallier,Pierre Peterlin,Alice Garnier,Thierry Guillaume,Amandine Le Bourgeois,Steven Le Gouill,Philippe Moreau,Cyrille Touzeau +16 more
TL;DR: A real-life single-center series of 49 consecutive patients with relapsed and refractory MM treated with the triplet pomalidomide cyclophosphamide dexamethasone (PCD) combination confirms that PCD combination is feasible and results in favorable response rate and PFS in comparison with pom Khalidomide dexamETHasone alone